Advertisement

Pharmacy

After several conflict-of-interest scandals, Memorial Sloan Kettering Cancer Center in New York City will bar top executives from serving on corporate boards of drug and healthcare companies that pay them, according to The New York Times.

In recent months, several drug giants announced they are exploring deals or have completed deals to expand their portfolios of cancer medications.

Advertisement

Snehal Doshi, PharmD, vice president of pharmacy services for Marietta, Ga.-based WellStar Health System, spoke with Becker's Hospital Review about the disruptors that have his attention and the skills pharmacy leaders need in today's rapidly changing healthcare climate.

After more than 30 drugmakers ushered in the new year with a wave of price hikes, another pharma giant, Johnson & Johnson, is following suit.

Biosimilars are reshaping the treatment landscape for biologic-based therapies. In addition to producing clinically-equivalent outcomes to their reference products, studies show biosimilars will contribute to lowering the overall cost of healthcare1.

Advertisement